Bristol Myers Squibb (BMS) has shared positive top-line results from two late-stage studies of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). The ...

Axsome Therapeutics has announced that it has successfully completed its late-stage clinical programme evaluating investigational AXS-05 (dextromethorphan-bupropion) in Alzheimer’s disease (AD) ...

Kearney Urology Center in the US has reported a 50% reduction in biopsies since adopting a new prostate cancer blood test with “unprecedented accuracy”. The test, EpiSwitch PSE, is the culmination of ...

Amgen’s Imdylltra (tarlatamab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with small cell lung cancer (SCLC). The drug has been specifically ...

Novartis has shared positive top-line results from a late-stage study of its investigational gene therapy in patients aged two to less than 18 years with the rare neuromuscular disease spinal muscular ...

BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab-jsgr) has been granted approval by the US Food and Drug Administration (FDA) as part of a first-line combination treatment for advanced gastric cancer.

Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders. This transformative series will showcase the 2025 Pharma ...

Is your medical education strategy reaching the right HCPs in the formats they prefer? Discover actionable insights to ...

AstraZeneca’s Tagrisso (osimertinib) has been approved by the European Commission (EC) to treat a new subset of lung cancer patients. The epidermal growth factor receptor (EGFR)-tyrosine kinase ...

As the world’s third largest pharmaceutical market, Japan accounted for approximately 6% of the $1.5tn in global pharmaceutical sales in 2022. While this makes it an attractive market for all ...

Pfizer’s Braftovi (encorafenib) regimen has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat metastatic colorectal cancer (mCRC). The drug has been authorised ...